Old arthritis drug paired with immune suppressant shows promise for tough lung cancers
NCT ID NCT01737502
First seen Nov 01, 2025 · Last updated Jun 24, 2026 · Updated 26 times
Summary
This study tested two drugs—auranofin (used for arthritis) and sirolimus (an immune suppressant)—in 29 people with advanced lung cancer that had stopped responding to standard treatments. The goal was to find a safe dose and see if the combination could slow cancer growth. The trial was completed, but results are limited by its small size and early phase.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
auranofin and sirolimus
What this could lead to
If it works, this could point toward a new treatment option for people with advanced lung cancer who have run out of standard therapies.
What could go wrong
This was a small, early-phase trial with only 29 participants, so results may not apply to everyone. The combination also caused side effects like low blood counts and mouth sores.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.